AFS/SERS Saliva-based SARS-CoV-2 Earliest Infection and Antibodies Detection

AFS/SERS 基于唾液的 SARS-CoV-2 最早感染和抗体检测

基本信息

批准号：
10266399
负责人：
Tony Jun Huang
金额：
$ 90.41万
依托单位：
UNIVERSITY OF CALIFORNIA LOS ANGELES
依托单位国家：
美国
项目类别：
财政年份：
2020
资助国家：
美国
起止时间：
2020-12-21 至 2023-11-30
项目状态：
已结题

来源：
https://reporter.nih.gov/project-details/10266399
关键词：
2019-nCoV Acute Antigens COVID-19 COVID-19 detection COVID-19 pandemic COVID-19 patient COVID-19 testing Clinical Collaborations Communication Programs Coupled Data Data Collection Data Coordinating Center Detection Development Emergency response Emerging Technologies FDA Emergency Use Authorization Funding Immunity Immunoglobulin A Immunoglobulin G Immunoglobulin M Infection Label Patients Performance Point of Care Technology Population Public Health RADx Radical RNA Raman Spectrum Analysis SARS-CoV-2 antibody SARS-CoV-2 immunity SARS-CoV-2 infection Saliva Sampling Surface Technology Testing United States National Institutes of Health Validation Viral Load result Virion Virus antibody detection antigen detection base data sharing exosome extracellular extracellular vesicles improved new technology particle point of care research clinical testing saliva sample salivary assay

项目摘要

Project Summary/Abstract: This U18 application is responsive to the NIH’s RADx-rad Emergency Responses to the COVID- pandemic for new or non-traditional technologies developed for single extracellular vesicle, exosome and extracellular RNA (exRNA) isolation and analysis and reposition them for detection of SARS-CoV-2. The applicant’s group is a grantee in the NIH Common Fund “Extracellular RNA Communication (ERC)” Program advancing a new and emerging technology of Acoustofluidic Separation (AFS) for label-free, high yield and purity exosomes from biofluids which is coupled to extracellular RNA characterization using Surface Enhanced Raman Spectroscopy (SERS) for single EV identification. This U18 application is to reposition the AFS EV technology and SERS for the non-invasive earliest detection of SARS-CoV-2 in saliva of infected patients. Host immunity to SARS-CoV-2 will also be assessed in the saliva samples, permitting the earliest detection of SARS-CoV-2 infection and host immunity non-invasively in a saliva sample. Five Specific Aims are in place to reposition the saliva-based AFS and SERS technologies, in a 2-year U18 proposal, to test the hypothesis that an integrated multi-parametric non-invasive saliva test for SARS-CoV- 2 infection, viral load and host immunity test demonstrating clinical performance surpassing current saliva-based SARS-CoV-2 EUA tests.

项目摘要/摘要：该U18应用程序对NIH的RADX RAD紧急响应有响应用于单个细胞外囊泡，外泌体和细胞外RNA（EXRNA）分离和分析并重新定位它们以检测SARS-COV-2。这申请人小组是NIH普通基金“细胞外RNA通信（ERC）”计划的受赠人推进一种新的和新兴的Acoustofluidic分离技术（AFS），以获得无标签，高收益和纯度来自生物流体的外泌体使用表面增强的拉曼耦合到细胞外RNA表征用于单个EV识别的光谱（SER）。该U18应用程序是重新定位AFS EV技术以及对感染患者唾液中SARS-COV-2最早检测的SERS。宿主免疫 SARS-COV-2还将在唾液样品中进行评估，允许最早发现SARS-COV-2 在唾液样本中非侵入性感染和宿主免疫学。在2年内重新定位基于唾液的AFS和SERS技术的五个具体目标是重新定位的。 U18提案，以检验以下假设：SARS-COV的综合多参数非侵入性唾液检验 2感染，病毒载荷和宿主免疫学测试证明临床性能超过了基于唾液的电流 SARS-COV-2 EUA测试。